Dec 30, 2025 • ts2.tech
SOMEWHAT-BEARISH
SRRK stock drops 3% today: What’s driving Scholar Rock shares as FDA reinspection nears
Scholar Rock (SRRK) shares dropped 3.2% today, reversing earlier gains, as investors remain focused on the timing of a year-end manufacturing reinspection crucial for its lead drug candidate, apitegromab. The FDA had previously issued an "official action indicated" status for a key manufacturing site, leading to a resubmission delay. The stock's near-term valuation hinges on regulatory timing, with a BLA resubmission anticipated in 2026 and a new fill-finish facility expected to commercial capacity by early 2026.
Dec 23, 2025 • MarketBeat
SOMEWHAT-BULLISH
Scholar Rock Holding Corporation $SRRK Shares Bought by Voya Investment Management LLC
Voya Investment Management LLC increased its stake in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 18.1% during the third quarter, bringing its total to 443,155 shares valued at $16.5 million. Institutional investors now collectively own 91.08% of the company, while insider activity showed mixed signals with a significant sale by Mo Qatanani and a purchase by director Srinivas Akkaraju. The company's stock, with a market cap of $4.61 billion, has been given an average "Buy" rating by analysts, with a consensus target price of $48.92, despite missing its recent EPS estimate.
Dec 15, 2025 • BioSpace
NEUTRAL
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 13, 2025
Scholar Rock (NASDAQ: SRRK) announced inducement equity awards for two newly hired employees, consisting of stock options for 4,457 shares and restricted stock units for 3,343 shares of its common stock. These grants are part of the Company’s 2022 Inducement Equity Plan, specifically under Nasdaq Listing Rule 5635(c)(4), designed to attract new talent. The awards vest over several years, subject to continued employment, with stock options having an exercise price matching the closing price on December 8, 2025.
Dec 13, 2025 • Stock Titan
SOMEWHAT-BULLISH
Scholar Rock (NASDAQ: SRRK) grants 7,800-share inducement awards at $45.25 exercise price
Scholar Rock (NASDAQ: SRRK) announced inducement equity awards covering 7,800 shares of its common stock to two new employees. These awards include stock options for 4,457 shares and restricted stock units for 3,343 shares, granted under the company's 2022 Inducement Equity Plan. The exercise price for the stock options is $45.25, reflecting the closing price on December 8, 2025.
Dec 11, 2025 • Investing.com
NEUTRAL
Scholar Rock stock rating reiterated as Overweight by Cantor Fitzgerald
Cantor Fitzgerald has reiterated its Overweight rating on Scholar Rock (NASDAQ:SRRK), maintaining a positive outlook due to high confidence in the approval prospects for its lead drug candidate, apitegromab. The stock is currently trading at $45.05 with a market capitalization of $4.6 billion, just below its 52-week high. Analyst Eric Schmidt expects apitegromab's approval to make Scholar Rock a top performer in 2026, aiming for a multi-billion dollar franchise.
Dec 10, 2025 • Investing.com
SOMEWHAT-BULLISH
Scholar Rock stock reaches 52-week high at 47.01 USD
Scholar Rock Holding Corp's stock has hit a 52-week high of $47.01 USD, marking a significant milestone for the biotechnology company with a 36.47% surge in the last six months. Despite positive investor sentiment and a Strong Buy consensus from analysts, InvestingPro suggests the stock may be overvalued relative to its Fair Value. The company recently reported mixed Q3 2025 earnings and is planning to resubmit its biologics license application for apitegromab in 2026, with several firms maintaining positive ratings despite an FDA setback.